Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)



Status:Available
Conditions:Neurology, Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:Any
Updated:12/3/2016
Contact:Biogen
Email:medinfo@biogen.com

Use our guide to learn which trials are right for you!

Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)

To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular
Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.

Availability of nusinersen at an existing clinical trial site will depend on territory
eligibility. Program opening date will depend on regulatory requirements and center-specific
factors. Participating sites will be added as they apply for the EAP. A doctor must decide
whether the potential benefit outweighs the risk of receiving an investigational therapy
based on the individual patient's medical history and program eligibility criteria

Key Inclusion Criteria:

- Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or
compound heterozygote.

- Onset of clinical signs and symptoms at ≤ 6 months (180 days) of age, consistent with
infantile onset, Type I SMA

- Patient whose care in the opinion of the treating physician meets, and is expected to
continue to meet, the guidelines set out in the 2007 Consensus Statement for Standard
of Care in SMA

Key Exclusion Criteria:

- Patient is qualified to participate in an ongoing clinical trial with nusinersen

- Participation in a prior nusinersen study

- Previous exposure to nusinersen

- History of brain or spinal cord disease that would interfere with the LP procedures
or CSF circulation

- Presence of implanted shunt for the drainage of CSF or implanted CNS catheter

- Previous or current participation in a clinical trial with an investigational gene
therapy for SMA

- Participation in a study with an investigational therapy for SMA within 6 months or
five half-lives of the investigational drug, whichever is the longer, prior to the
first dose of nusinersen.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
We found this trial at
5
sites
13535 Nemours Parkway
Orlando, Florida 32827
(407) 567-4000
Nemours Children's Hospital Nemours Children's Hospital in Orlando brings pediatric specialty care never before offered...
?
mi
from
Orlando, FL
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60614
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Randwick, New South Wales 2031
?
mi
from
Randwick,
Click here to add this to my saved trials